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EDITORIAL Open Access
The new aims and scope of Arthritis
Research & Therapy
Christopher D. Buckley1,2* and Harris Perlman3*
Aims and scope of Arthritis Research & Therapy
What should the aim, scope and ambition of a journal
be? After two years as Editors-in-Chief of Arthritis Re-
search & Therapy [1], we have been reviewing this ques-
tion with our Editorial Board; not so much to produce a
mission statement, but more to ensure that we continue
to be relevant to our community of authors and readers.
Names matter. They convey identity and uniqueness. So
we spent some time discussing our journal’s name as
well as its scope and what niche it should occupy in a
crowded and growing field. Most members of the Board
like our name. The brand is established, distinctive and
we hope conveys the two themes we want to promote;
research and therapy. However, we are keen to showcase
not just arthritis, but the full range of autoimmune
rheumatic and musculoskeletal conditions. We hope that
our community will agree that we are notable for the
breadth, quality and significance of emerging and ex-
ploratory studies; from pre-clinical to clinical sciences.
We are particularly keen to emphasise the following
points:
 We aim to be a broad, online and independent
journal with a global readership and community of
authors (Fig. 1) that inspires the next generation of
rheumatologists. In celebration of our global reach
we have commissioned commentaries from colleagues
around the globe and asked them to give us their
perspective of the state of musculoskeletal science in
their geographic area [2]. As patients (as well as those
looking after them) now actively access our journal
we want to provide the highest quality of information
not just to scientists, but also care workers and our
patient population regardless of their location. By
being open access and published under the CC BY
license, all articles published in Arthritis Research &
Therapy are freely available to communities around
the world.
 Like all journals, we strive for fair and fast peer
review. We are unusual in having two Editors-in-
Chief (in two different continents) and we have
established a strong group of experts who handle
submissions across our six sections: Immunology
and Pathology, Pharmacology and Therapeutics,
Epidemiology and Clinical Trials, Bone and Cartilage
Biology, Imaging and Outcomes, Genetics and
Epigenetics.
 We would like to highlight emerging and exploratory
studies and in particular we would like to be the
journal of choice for informative science linked to
clinical trials. We don’t believe that basic science can
only be successfully conducted in animal models.
Animals model processes; humans display the
pathology.
 We would like to be a journal that publishes across
the wide spectrum of autoimmune rheumatic and
musculoskeletal conditions. Clinical trials are
changing and new devices and diagnostic tests are
emerging which will be subjected not just to the
current test of “equivalence” but which will now
need to be tested in randomised clinical studies. We
want to be at the forefront of publishing the science
that accompanies these trials, as well as the new
methodologies on which they are based.
So in summary we hope that the following statement
accurately summarizes these points and reflects the
scope of our journal:
“Established in 1999, Arthritis Research and Therapy
is an international, open access, peer-reviewed journal,
publishing original articles in the area of musculoskeletal
research and therapy as well as reviews, commentaries
and reports.
A major focus of the journal is on the immunologic
processes leading to inflammation, damage and repair as
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they relate to autoimmune rheumatic and musculoskel-
etal conditions, and which inform the translation of this
knowledge into advances in clinical care.
Original basic, translational and clinical research is
considered for publication along with results of early
and late phase therapeutic trials, especially as they per-
tain to the underpinning science that informs clinical
observations in interventional studies.”
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Fig. 1 Geographical distribution of articles published in Arthritis
Research & Therapy between September 2016 and September 2017,
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